Provexis (PXS) AI Stock Analysis

• Market Cap: £25.80M
• Dividend Yield: N/A
• Average Volume (3M): 426.62K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.13
• Revenue Growth: 61.13%
• EPS Growth: 33.33%
• Country: UK
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 2,345,891,400
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 426,617
• PEG Ratio: 0.68
• Price to Book (P/B): 7.92
• Price to Sales (P/S): 7.95
• P/FCF Ratio: -30.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: 1.00p ▲(40.85% Upside)

The score is held back primarily by weak financial performance—ongoing losses and cash burn—despite the benefit of zero debt. Technicals are a clear positive with strong trend and momentum, but valuation remains pressured due to negative earnings and no indicated dividend support.

Positive Factors

Proprietary ingredient & B2B model

Proprietary, science-backed Fruitflow® and a B2B ingredient/licensing model create an asset-light, scalable revenue route. Selling to manufacturers lets Provexis leverage partners' distribution, enabling recurring ingredient revenue without heavy retail infrastructure investment.

Accelerating revenue growth

Sharp top-line acceleration signals improving commercial traction and partner adoption. If sustained, this trend supports scale economics, higher absorption of fixed costs and better margin leverage, improving the company's ability to move from small-scale losses toward profitability.

Debt-free balance sheet

No reported debt lowers refinancing and interest-rate risk and preserves financial flexibility. This conservatism gives time to execute commercial rollouts and reduces mandatory cash drains, improving runway compared with peers that rely on leverage to fund growth.

Negative Factors

Persistent unprofitability

Consistent operating and net losses, with deeply negative margins, reflect structural inability to cover costs at current scale. Without sustained margin improvement or scale, profitability risk persists, constraining reinvestment capacity and threatening long-term viability.

Negative operating and free cash flow

Ongoing cash burn forces reliance on external funding or dilution to finance growth. Persistent negative OCF/FCF limits ability to invest in partner support, marketing, or R&D, increasing execution and runway risk unless revenues continue to scale materially.

Very small scale and weak returns

Low equity base, deeply negative ROE and a tiny operating footprint (employees: 2) indicate limited scale and operational depth. Small size magnifies execution risk, reduces bargaining power with partners, and makes achieving durable margins and self-sustaining cash flow harder.

Provexis Business Overview & Revenue Model

Company Description

Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in foods, beverages, and dietary supplement formats. It also offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and normal heart function. Provexis plc has a collaboration agreement with By-Health Co., Ltd. The company offers its products through retail stores, as well as online. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.

How the Company Makes Money

Provexis makes money primarily through the commercialization of its Fruitflow technology. The company generates revenue by licensing Fruitflow to manufacturers and distributors in the food and dietary supplement industries, allowing them to incorporate the ingredient into their products. Additionally, Provexis engages in collaborative partnerships and agreements with other companies to co-develop and market new products that incorporate its proprietary technology. These partnerships often involve upfront payments, milestone payments, and royalties based on product sales. The company's focus on intellectual property and innovation ensures a recurring revenue stream through licensing deals and collaborative ventures.

Provexis Financial Statement Overview

Summary

Revenue growth is accelerating sharply off a small base, and the balance sheet has no debt (lower financial risk). However, profitability remains weak with persistent operating/net losses and ongoing negative operating and free cash flow, keeping the score below average.

Income Statement

Revenue growth is improving, accelerating from roughly 106% (FY2024) to about 771% (FY2025), indicating better commercial traction off a small base. However, profitability remains weak: the company is still loss-making with negative operating profit and net income in every year provided, and FY2024 margins were deeply negative (net margin about -73% and operating margin about -75%). Overall, the top-line trend is a positive, but losses and poor margin structure keep the income statement score low.

Balance Sheet

The balance sheet is conservatively financed with zero total debt across all reported years, reducing refinancing and interest-rate risk. Equity is positive (about 1.30M in FY2025) and has improved versus FY2024, but returns remain negative (FY2024 return on equity around -81%), reflecting ongoing losses and limiting the quality of equity. Overall, the lack of leverage is a key strength, offset by weak profitability and smaller scale.

Cash Flow

Cash generation remains a key concern: operating cash flow and free cash flow are negative in every year shown (FY2025 operating/free cash flow about -339k). While free cash outflow improved materially versus FY2023 (as reflected in the strong free cash flow growth figure), the business is still consuming cash, which raises funding risk if losses persist. Overall, improving trend but still structurally negative cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.29M	1.29M	801.96K	389.92K	426.17K	505.33K
Gross Profit	532.94K	532.94K	283.80K	294.42K	380.05K	456.19K
EBITDA	-302.99K	-449.63K	-603.59K	0.00	0.00	0.00
Net Income	-452.72K	-452.72K	-586.24K	-385.24K	-224.25K	-341.01K
Balance Sheet
Total Assets	1.01M	1.01M	498.04K	845.99K	1.13M	1.29M
Cash, Cash Equivalents and Short-Term Investments	708.09K	708.09K	189.36K	379.12K	863.87K	1.08M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	248.21K	248.21K	307.45K	188.34K	157.91K	150.68K
Stockholders Equity	1.30M	1.30M	724.34K	1.19M	1.50M	1.66M
Cash Flow
Free Cash Flow	-339.79K	-338.90K	-191.50K	-519.85K	-213.79K	-262.32K
Operating Cash Flow	-339.79K	-338.90K	-191.50K	-519.85K	-213.54K	-262.07K
Investing Cash Flow	890.00	1.93K	1.73K	887.00	78.00	-250.00
Financing Cash Flow	857.63K	857.63K	0.00	35.10K	1.05M	1.05M

Provexis Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.71
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PXS, the sentiment is Positive. The current price of 0.71 is below the 20-day moving average (MA) of 1.02, below the 50-day MA of 0.80, and above the 200-day MA of 0.69, indicating a bullish trend. The MACD of 0.08 indicates Positive momentum. The RSI at 65.71 is Neutral, neither overbought nor oversold. The STOCH value of 49.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:PXS.

Provexis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EAH	76 Outperform	£76.23M	25.22	3.62%	―	1.44%	359.79%
STX	63 Neutral	£114.81M	-5.78	-396.71%	―	93.48%	51.18%
PXS	53 Neutral	£25.80M	-36.67	-51.21%	―	61.13%	33.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CHLL	43 Neutral	£3.53M	-1.18	―	―	―	―
N4P	42 Neutral	£3.95M	-1.98	-73.08%	―	―	―

Provexis Corporate Events

Provexis Hit by Interim Sales Dip as Supply Delay Masks Expanding Fruitflow Pipeline

Provexis reported unaudited interim revenue of £364,000 for the six months to 30 September 2025, sharply lower than the prior year due to a third‑party delay in a new production run of its Fruitflow II SD ingredient, which temporarily constrained sales in August and September. Despite the short-term impact, the company has since sold out its legacy DSM-sourced inventory, booked and/or taken orders worth several hundred thousand pounds for Fruitflow II SD after the period end, and is planning at least three new production runs over the next 12 months, while continuing to deepen its commercial ties with dsm-firmenich and support BYHEALTH’s large-scale, regulatory-driven launch plans in China that could significantly expand Fruitflow’s global footprint and enhance Provexis’s long-term growth prospects.

The most recent analyst rating on (GB:PXS) stock is a Hold with a £0.82 price target. To see the full list of analyst forecasts on Provexis stock, see the GB:PXS Stock Forecast page.

Provexis Secures Shareholder Support and Advances in Chinese Market

Provexis plc announced that all resolutions were passed at its Annual General Meeting, reflecting strong shareholder support. The company continues to make strides in the Chinese market with its Fruitflow ingredient, as BYHEALTH has submitted applications for new health function claims, indicating significant investment and potential growth in the region.